62-year-old man presents with hematuria and pain in the right flank. Further work-up reveals the presence of a right kidney mass and a left lower lobe lung mass. A kidney and lung biopsy are performed. What is your diagnosis?
Interim Phase III COMBI-d Results Show PFS Benefit in Patients With BRAF V600E/K Mutant Metastatic Melanoma
CHICAGO— Interim results of the ongoing phase III COMBI-d study reported at the 2014 annual meeting of the American Society of Clinical Oncology (ASCO) show that patients with BRAF V600E/K mutant metastatic melanoma had a signifi
The growing understanding of cancer biology has demanded that the design of cancer clinical trials evolve as well to optimize translation of the findings in a timely, but safe way for patients. One example of this is the “basket trial” d
While seven drugs have been approved for clear cell renal cell carcinoma (ccRCC) since 2005, the most appropriate systemic therapy for non-clear cell renal cell carcinoma (nccRCC) is unknown.
A 37-year-old woman presents with general malaise and swelling of her axillary lymph nodes. Surgical resection of a lymph node is performed.
What is your diagnosis?
Clinicians who treat patients with high-grade serous ovarian cancer (HGSOC) may soon have a better way to decide whether the patient could respond to the anti-angiogenesis antibody bevacizumab (Avastin).
Long-term results from a phase I study demonstrate that concurrent treatment with ipilimumab and nivolumab led to an unprecedented improvement in survival for patients with advanced melanoma.
The story of how the targeted therapies, immunotherapies, and combinations of these therapies have been developed for use in patients with advanced melanoma holds a number of important lessons for the development of agents for use in other tumor types.
CHICAGO--In light of encouraging data from a phase II trial reported at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), the National Cancer Institute (NCI) plans to conduct two phase III clinical tr
On Monday during ASCO, Dr. Axel Hauschild reviewed the role of intralesional therapy in melanoma in a sub-session of the melanoma abstract review talk entitled “Evolving Utility of Intralesional Therapy for Melanoma.”
In my opinion, the two predominant themes at the 50th annual ASCO meeting this year were genomics and immune therapies.
Targeting angiogenesis in cancer dates back to the 1970s, when the first anti-angiogenesis inhibitor, bevacizumab, was described to “starve tumors.” Of course in breast cancer, there was a lot of excitement when bevacizumab was granted ac
Researchers have demonstrated the ability to detect AR-V7 in circulating tumor cells of prostate cancer patients with primary resistance to enzalutamide and abiraterone.
As part of our coverage of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, we discuss some of the immunotherapy treatment options for urological cancers.
A 67-year-old man presents with abdominal pain and bloody stools. Diagnostic imaging reveals the presence of a mass in the right colon and a solitary mass in the liver. Sections of the colon mass and liver are shown. What is your diagnosis?